Entera Bio (ENTX) Net Margin (2019 - 2025)

Entera Bio (ENTX) has reported Net Margin for 6 consecutive years, with 6235.71% the latest figure, recorded in Q1 2025.

• Quarterly Net Margin changed N/A year-over-year to 6235.71% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 28383.33% (down 2292698.0% YoY) and the FY2025 annual result came in at 27235.71%, down 2196444.0% from the prior year.
• Net Margin declined to 6235.71% in Q1 2025 per ENTX's latest filing, from 2875.61% in the prior quarter.
• Over the last five years, Net Margin for ENTX reached as high as 1462.42% in Q1 2021 and fell as low as 38337.5% in Q3 2022.
• A 4-year average of 8500.23% and a median of 4918.32% in 2022 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2021 — Net Margin surged 377040 bps — and 2022, when it tumbled 3604179 bps.
• Year by year, Net Margin stood at 2484.85% in 2021, then tumbled by 772 bps to 21678.57% in 2022, then surged by 87 bps to 2875.61% in 2024, then slumped by 117 bps to 6235.71% in 2025.
• According to Business Quant data, Net Margin over the past three periods registered 6235.71%, 2875.61%, and 7192.86% for Q1 2025, Q4 2024, and Q3 2024 respectively.